1. Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells
   Carolyne Falank et al, 2016, Frontiers in Endocrinology CrossRef
2. Anti‐proliferative effect of rosiglitazone in the human T‐lymphocyte leukaemia cell line Jurkat cells
   Rui Wei et al, 2018, Cell Biology International CrossRef
3. New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers
   Yi-Fan Dang et al, 2018, Chemico-Biological Interactions CrossRef
4. Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway
   Hong-Yuan Wang et al, 2016, Biomedicine & Pharmacotherapy CrossRef
5. Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
   Chin-Hsiao Tseng, 2023, Cancers CrossRef
6. PPAR-γ Modulators as Current and Potential Cancer Treatments
   Tiange Chi et al, 2021, Frontiers in Oncology CrossRef
7. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling
   Amreen Mughal et al, 2015, European Journal of Pharmacology CrossRef
8. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway
   NAN FENG et al, 2016, Molecular Medicine Reports CrossRef
9. Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy
   Adam Hermawan et al, 2022, BMC Genomic Data CrossRef